Iron Triangle Partners
Latest statistics and disclosures from Iron Triangle Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CVS, DXCM, ABBV, MDT, CRL, and represent 35.38% of Iron Triangle Partners's stock portfolio.
- Added to shares of these 10 stocks: DXCM (+$57M), LLY (+$38M), RGEN (+$36M), MDGL (+$27M), JAZZ (+$20M), NBIX (+$18M), WST (+$18M), VCYT (+$17M), FOLD (+$16M), EXAS (+$11M).
- Started 10 new stock positions in VCYT, JAZZ, LLY, WST, DXCM, IDYA, FOLD, MDGL, NBIX, RGEN.
- Reduced shares in these 10 stocks: MMSI (-$37M), , , , , OSCR (-$19M), DOCS (-$19M), TWST (-$16M), ONC (-$15M), NVST (-$12M).
- Sold out of its positions in ALNY, ONC, EHAB, NVST, HCA, INSM, PODD, ISRG, MMSI, OSCR. TWST, ICLR.
- Iron Triangle Partners was a net buyer of stock by $7.1M.
- Iron Triangle Partners has $703M in assets under management (AUM), dropping by 8.00%.
- Central Index Key (CIK): 0001779763
Tip: Access up to 7 years of quarterly data
Positions held by Iron Triangle Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Iron Triangle Partners
Iron Triangle Partners holds 25 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| CVS Caremark Corporation (CVS) | 8.6 | $60M | +6% | 798k | 75.39 |
|
| Dex (DXCM) | 8.1 | $57M | NEW | 850k | 67.29 |
|
| Abbvie (ABBV) | 6.6 | $46M | -19% | 200k | 231.54 |
|
| Medtronic SHS (MDT) | 6.1 | $43M | +13% | 453k | 95.24 |
|
| Charles River Laboratories (CRL) | 6.0 | $42M | -16% | 268k | 156.46 |
|
| Eli Lilly & Co. (LLY) | 5.4 | $38M | NEW | 50k | 763.00 |
|
| Brightspring Health Svcs (BTSG) | 5.2 | $37M | +3% | 1.2M | 29.56 |
|
| Repligen Corporation (RGEN) | 5.1 | $36M | NEW | 270k | 133.67 |
|
| Glaukos (GKOS) | 4.0 | $28M | +26% | 343k | 81.55 |
|
| Tenet Healthcare Corp Com New (THC) | 4.0 | $28M | -27% | 137k | 203.04 |
|
| EXACT Sciences Corporation (EXAS) | 3.9 | $27M | +66% | 500k | 54.71 |
|
| Adaptive Biotechnologies Cor (ADPT) | 3.9 | $27M | +21% | 1.8M | 14.96 |
|
| Madrigal Pharmaceuticals (MDGL) | 3.8 | $27M | NEW | 58k | 458.66 |
|
| Guardant Health (GH) | 3.6 | $25M | +33% | 400k | 62.48 |
|
| Brookdale Senior Living (BKD) | 3.4 | $24M | +66% | 2.8M | 8.47 |
|
| Cardinal Health (CAH) | 3.1 | $22M | +31% | 138k | 156.96 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.8 | $20M | NEW | 150k | 131.80 |
|
| Neurocrine Biosciences (NBIX) | 2.6 | $18M | NEW | 131k | 140.38 |
|
| West Pharmaceutical Services (WST) | 2.6 | $18M | NEW | 70k | 262.33 |
|
| Adapthealth Corp Common Stock (AHCO) | 2.4 | $17M | 1.9M | 8.95 |
|
|
| Veracyte (VCYT) | 2.4 | $17M | NEW | 485k | 34.33 |
|
| Amicus Therapeutics (FOLD) | 2.2 | $16M | NEW | 2.0M | 7.88 |
|
| Doximity Cl A (DOCS) | 2.2 | $15M | -55% | 210k | 73.15 |
|
| Ideaya Biosciences (IDYA) | 1.0 | $7.3M | NEW | 270k | 27.21 |
|
| Argenx Se Sponsored Adr (ARGX) | 1.0 | $7.3M | -36% | 9.9k | 737.56 |
|
Past Filings by Iron Triangle Partners
SEC 13F filings are viewable for Iron Triangle Partners going back to 2019
- Iron Triangle Partners 2025 Q3 filed Nov. 14, 2025
- Iron Triangle Partners 2025 Q2 filed Aug. 14, 2025
- Iron Triangle Partners 2025 Q1 filed May 15, 2025
- Iron Triangle Partners 2024 Q4 filed Feb. 14, 2025
- Iron Triangle Partners 2024 Q3 filed Nov. 14, 2024
- Iron Triangle Partners 2024 Q2 filed Aug. 14, 2024
- Iron Triangle Partners 2024 Q1 filed May 15, 2024
- Iron Triangle Partners 2023 Q4 filed Feb. 14, 2024
- Iron Triangle Partners 2023 Q3 filed Nov. 14, 2023
- Iron Triangle Partners 2023 Q2 filed Aug. 14, 2023
- Iron Triangle Partners 2023 Q1 filed May 15, 2023
- Iron Triangle Partners 2022 Q4 filed Feb. 14, 2023
- Iron Triangle Partners 2022 Q3 filed Nov. 14, 2022
- Iron Triangle Partners 2022 Q2 filed Aug. 15, 2022
- Iron Triangle Partners 2022 Q1 filed May 16, 2022
- Iron Triangle Partners 2021 Q4 filed Feb. 14, 2022